Consensus Is Essential To Find Best Value-Added Path
Insists Medicines For Europe’s Value Added Medicines Chair Arun Narayan
Finding a consensus across European stakeholders on how best to recognize and reward the benefits of value added medicines is key to the sector’s success, says Arun Narayan – chairman of the value added medicines sector group at Medicines for Europe and also head of global portfolio strategy and head of European business operations at Mylan – in an exclusive interview with Generics Bulletin.
You may also be interested in...
Celltrion says it is ready to roll out its Remsima SC subcutaneous infliximab in Europe in the first quarter of 2020, after receiving a formal pan-European marketing authorization from the European Commission.
Incentives for innovation around known molecules and new guidelines for value added medicines are needed, Medicines for Europe has insisted at the organization’s value added medicines conference in Brussels yesterday. The European off-patent industry association has called for a “pragmatic value framework” to recognize value added medicines, as well as welcoming the advent of digital health solutions.
Belgium’s recent royal decree on pharmaceutical reimbursement represents “three significant steps forward for the generic medicines sector”, according to local off-patent industry association FeBelGen. As well as simplifying reimbursement, the association points out, the decree also sets out a reimbursement pathway for value-added medicines as well as removing certain packaging requirements.